Vorozole

Vorozole
	File:Vorozole.svg
Systematic (IUPAC) name
	6-[(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-; 1-methyl-benzotriazole
Pharmacokinetic data
Bioavailability	Very high
Metabolism	Hepatic
Biological half-life	8 hours
Identifiers
CAS Number	118949-22-7
ATC code	L02BG05 (WHO)
PubChem	CID 60796
Chemical data
Formula	C16H13ClN6
Molar mass	324.768 g/mol[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vorozole is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.

It is selective.^[1]

Chemistry

File:Vorozole synth.svg

Prous, J.; Grant, J.; Castaner, J.; Drugs Future 1994, 457.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

40px	This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. v d e

↑ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Res. Treat. 49 Suppl 1: S59–65; discussion S73–7. PMID 9797019.

[pmid9797019-1] Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Res. Treat. 49 Suppl 1: S59–65; discussion S73–7. PMID 9797019.

[1]

Vorozole

Chemistry

References

Navigation menu

Views

Personal tools

Navigation

Search

Tools

adverts